ER、PR及HER-2受体在乳腺癌原发灶及复发灶间表达差异及意义  

作　　者：陈志萍[1] 李金高[1] 黄传生[1] 

机构地区：[1]南昌大学医学院

出　　处：《临床医药实践》2009年第5Z期1653-1655,共3页Proceeding of Clinical Medicine

摘　　要：目的:乳腺癌内分泌治疗及免疫靶向药物赫赛汀生物治疗的前提是相应的雌激素受体、孕激素受体的阳性表达及HER-2癌基因蛋白的过表达。目前对复发转移的乳腺癌病例受体表达情况的判断主要依据原发灶,而忽略了原发灶和复发转移灶之间可能存在的差异。本研究着重研究ER、PR及HER-2癌基因蛋白在乳腺癌原发灶及复发转移灶之间的表达差异,探讨其临床意义。方法:采用免疫组织化学检测45例乳腺癌患者原发灶及复发灶中ER、PR及HER2表达,分析研究ER、PR及HER2的变化率。结果:原发灶中ER、PR的阳性率分别为62.2%,60%(28/45,27/45),明显高于复发灶(37.8%17/45,31.1%14/45)(P【0.01)。复发灶中HER-2阳性率为62.2%(28/45),明显高于原发灶(26.7%12/45)(P【0.01)。结论:ER、PR及HER-2癌基因蛋白在乳腺癌原发灶和复发灶之间的表达存在显著性差异,所以在对复发乳腺癌进行临床治疗时,应考虑上述3种指标在复发灶中的确切状况。Objective:Hormone and Herceptin therapy for meta-static breast cancer is commonly based on expression of estrogen receptor (ER) and progestin receptor (PR) ,over-expression of HER-2 in primary breast cancer ,but studies comparing receptor status in primary and recurrence focuses of the same patient are limited.This study was designed to investigate discordance of ER,PR,and HER-2 status between primary and recurrence focuses of breast cancer.Methods:Immunohistochemistry assay was used to detect expression of ER,PR,and HER-2 in primary and recurrence focuses of 45 cases of breast cancer.The discordance of the three factors was analyzed,if which have correlation with clinical stage,pathological types,chemotherapy and endo-crine therapy.Results:Postive rate of ER, PR in primary focuses is 62.2%,60%(28/45,27/45),respectly,significantly higher than that in recurrence focuses(37.8% 17/45, 31.1% 14/45)(P<0.01).Postive rate of HER-2 in recurrence focuses is 62.2 %(28/45),significantly higher than that in primary focuses (26.7% 12/45) (P<0.01). Conclusions:Differences in expression level of ER,PR, and HER between primary and recurrence focuses of breast cancer were significant,so we should think highly of the differences expression of ER,PR,HER-2 in our clinical practices.

关 键 词：乳腺癌 激素受体 HER-2受体 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]